Breast cancer and incidence of type 2 diabetes mellitus: a systematic review and meta-analysis.
Aromatase inhibitors
Breast cancer
Endocrine therapy
Meta-analysis
Tamoxifen
Type 2 diabetes mellitus
Journal
Breast cancer research and treatment
ISSN: 1573-7217
Titre abrégé: Breast Cancer Res Treat
Pays: Netherlands
ID NLM: 8111104
Informations de publication
Date de publication:
Nov 2023
Nov 2023
Historique:
received:
27
04
2023
accepted:
06
07
2023
medline:
18
9
2023
pubmed:
1
9
2023
entrez:
1
9
2023
Statut:
ppublish
Résumé
Breast cancer and its treatments may increase the risk of type 2 diabetes (T2D). We conducted a systematic review and meta-analysis to investigate the association between breast cancer and the incidence of T2D overall, and according to breast cancer treatments. We searched PubMed, Embase and references of relevant papers for studies on breast cancer, breast cancer treatment, and subsequent T2D risk. Using random-effects models, we calculated effect estimates and associated 95% confidence intervals of the association between breast cancer, adjuvant breast cancer treatments (i.e., endocrine therapy (tamoxifen, aromatase inhibitors, and combined) and chemotherapy), and subsequent T2D. We used funnel plots to assess publication bias. Among 15 eligible studies, 10 reported on T2D risk after breast cancer, chemotherapy, or endocrine therapy; five studies investigated more than one association. Compared with patients without breast cancer, those with breast cancer and those who received any endocrine therapy had elevated risk of incident T2D (EE = 1.23, 95% CI = 1.13-1.33 and EE = 1.23, 95% CI = 1.16-1.32, respectively). Among breast cancer patients only, the risk of T2D was higher for those who received tamoxifen compared with those who did not receive tamoxifen (EE = 1.28, 95% CI = 1.18-1.38). Due to few studies, analyses investigating T2D risk after treatment with aromatase inhibitors or chemotherapy were inconclusive. Our findings suggest an elevated risk of T2D in breast cancer survivors, particularly after tamoxifen therapy. Further research is needed to determine the impact of aromatase inhibitors, and chemotherapy on the incidence of T2D after breast cancer.
Identifiants
pubmed: 37656235
doi: 10.1007/s10549-023-07043-6
pii: 10.1007/s10549-023-07043-6
pmc: PMC10504120
doi:
Substances chimiques
Aromatase Inhibitors
0
Tamoxifen
094ZI81Y45
Types de publication
Meta-Analysis
Systematic Review
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
11-22Subventions
Organisme : Novo Nordisk Fonden
ID : NNF20OC0065928
Organisme : Kræftens Bekæmpelse
ID : R328-A19070
Informations de copyright
© 2023. The Author(s).
Références
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J Clin 71(3):209–249
doi: 10.3322/caac.21660
Siegel RL, Miller KD, Fuchs HE, Jemal A (2022) Cancer statistics, 2022. CA Cancer J Clin 72(1):7–33
doi: 10.3322/caac.21708
pubmed: 35020204
Lipscombe LL, Chan WW, Yun L, Austin PC, Anderson GM, Rochon PA (2013) Incidence of diabetes among postmenopausal breast cancer survivors. Diabetologia 56(3):476–483
doi: 10.1007/s00125-012-2793-9
pubmed: 23238788
Hwangbo Y, Kang D, Kang M, Kim S, Lee EK, Kim YA, Chang YJ, Choi KS, Jung SY, Woo SM et al (2018) Incidence of diabetes after cancer development: a Korean national cohort study. JAMA Oncol 4(8):1099–1105
doi: 10.1001/jamaoncol.2018.1684
pubmed: 29879271
pmcid: 6143049
Wang CY, Shih SR, Huang KC (2020) Increasing risk of diabetes mellitus in postmenopausal women with newly diagnosed primary breast cancer. J Diabetes Investig 11(2):490–498
doi: 10.1111/jdi.13112
pubmed: 31271520
Lipscombe LL, Fischer HD, Yun L, Gruneir A, Austin P, Paszat L, Anderson GM, Rochon PA (2012) Association between tamoxifen treatment and diabetes: a population-based study. Cancer 118(10):2615–2622
doi: 10.1002/cncr.26559
pubmed: 21935915
Sun LM, Chen HJ, Liang JA, Li TC, Kao CH (2014) Association of tamoxifen use and increased diabetes among asian women diagnosed with breast cancer. Br J Cancer 111(9):1836–1842
doi: 10.1038/bjc.2014.488
pubmed: 25225901
pmcid: 4453737
Wolf I, Sadetzki S, Gluck I, Oberman B, Ben-David M, Papa MZ, Catane R, Kaufman B (2006) Association between diabetes mellitus and adverse characteristics of breast cancer at presentation. Eur J Cancer 42(8):1077–1082
doi: 10.1016/j.ejca.2006.01.027
pubmed: 16574404
Hamood R, Hamood H, Merhasin I, Keinan-Boker L (2018) Diabetes after hormone therapy in breast cancer survivors: a case-cohort study. J Clin Oncol 36(20):2061–2069
doi: 10.1200/JCO.2017.76.3524
pubmed: 29688833
Bordeleau L, Lipscombe L, Lubinski J, Ghadirian P, Foulkes WD, Neuhausen S, Ainsworth P, Pollak M, Sun P, Narod SA (2011) Diabetes and breast cancer among women with BRCA1 and BRCA2 mutations. Cancer 117(9):1812–1818
doi: 10.1002/cncr.25595
pubmed: 21509758
Nadal A, Alonso-Magdalena P, Soriano S, Quesada I, Ropero AB (2009) The pancreatic β-cell as a target of estrogens and xenoestrogens: implications for blood glucose homeostasis and diabetes. Mol Cell Endocrinol 304(1):63–68
doi: 10.1016/j.mce.2009.02.016
pubmed: 19433249
Yan H, Yang W, Zhou F, Li X, Pan Q, Shen Z, Han G, Newell-Fugate A, Tian Y, Majeti R et al (2019) Estrogen improves insulin sensitivity and suppresses gluconeogenesis via the transcription factor Foxo1. Diabetes 68(2):291
doi: 10.2337/db18-0638
pubmed: 30487265
Miller WR (2003) Aromatase inhibitors: mechanism of action and role in the treatment of breast cancer. Semin Oncol 30:3–11
doi: 10.1016/S0093-7754(03)00302-6
pubmed: 14513432
Le May C, Chu K, Hu M, Ortega CS, Simpson ER, Korach KS, Tsai M-J, Mauvais-Jarvis F (2006) Estrogens protect pancreatic beta-cells from apoptosis and prevent insulin-deficient diabetes mellitus in mice. Proc Natl Acad Sci USA 103(24):9232–9237
doi: 10.1073/pnas.0602956103
pubmed: 16754860
pmcid: 1482595
Johansson H, Gandini S, Guerrieri-Gonzaga A, Iodice S, Ruscica M, Bonanni B, Gulisano M, Magni P, Formelli F, Decensi A (2008) Effect of fenretinide and low-dose tamoxifen on insulin sensitivity in premenopausal women at high risk for breast cancer. Cancer Res 68(22):9512–9518
doi: 10.1158/0008-5472.CAN-08-0553
pubmed: 19010927
pmcid: 2599903
Ye F, Wen J, Yang A, Wang Y, Li N, Yu P, Wei W, Tang J (2021) The influence of hormone therapy on secondary diabetes mellitus in breast cancer: a meta-analysis. Clin Breast Cancer 22:e48–e58
doi: 10.1016/j.clbc.2021.06.014
pubmed: 34429242
Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372:n71
doi: 10.1136/bmj.n71
pubmed: 33782057
pmcid: 8005924
Dekkers OM, Vandenbroucke JP, Cevallos M, Renehan AG, Altman DG, Egger M (2019) COSMOS-E: guidance on conducting systematic reviews and meta-analyses of observational studies of etiology. PLoS Med 16(2):e1002742
doi: 10.1371/journal.pmed.1002742
pubmed: 30789892
pmcid: 6383865
Green MS, Symons MJ (1983) A comparison of the logistic risk function and the proportional hazards model in prospective epidemiologic studies. J Chronic Dis 36(10):715–723
doi: 10.1016/0021-9681(83)90165-0
pubmed: 6630407
Accordino MK, Wright JD, Buono D, Lin A, Huang Y, Neugut AI, Hillyer GC, Hershman DL (2020) Incidence and predictors of diabetes mellitus after a diagnosis of early-stage breast cancer in the elderly using real-world data. Breast Cancer Res Treat 183(1):201–211
doi: 10.1007/s10549-020-05756-6
pubmed: 32591988
pmcid: 8403515
Choi Y-J, Bak K, Yeo Y, Choi Y, Shin S (2021) Incident type 2 diabetes risk of selective estrogen receptor modulators in female patients with breast cancer. Pharmaceuticals 14(9):925
doi: 10.3390/ph14090925
pubmed: 34577625
pmcid: 8472249
Ji GY, Jin LB, Wang RJ, Bai Y, Yao ZX, Lu LJ, Huang JB, Liu SC, Li HY, Wang ZW et al (2013) Incidences of diabetes and prediabetes among female adult breast cancer patients after systemic treatment. Med Oncol 30(3):687
doi: 10.1007/s12032-013-0687-4
pubmed: 23925668
Juanjuan L, Wen W, Zhongfen L, Chuang C, Jing C, Yiping G, Changhua W, Dehua Y, Shengrong S (2015) Clinical pathological characteristics of breast cancer patients with secondary diabetes after systemic therapy: a retrospective multicenter study. Tumour Biol 36(9):6939–6947
doi: 10.1007/s13277-015-3380-8
pubmed: 25854171
Kwan ML, Cheng RK, Iribarren C, Neugebauer R, Rana JS, Nguyen-Huynh M, Shi Z, Laurent CA, Lee VS, Roh JM et al (2022) Risk of cardiometabolic risk factors in women with and without a history of breast cancer: the pathways heart study. J Clin Oncol 0(0):JCO2101738
Ng HS, Koczwara B, Roder D, Niyonsenga T, Vitry A (2018) Incidence of comorbidities in women with breast cancer treated with tamoxifen or an aromatase inhibitor: an australian population-based cohort study. J Comorb 8(1):16–24
doi: 10.15256/joc.2018.8.125
pubmed: 29651409
pmcid: 5885067
Ng HS, Koczwara B, Roder DM, Niyonsenga T, Vitry AI (2018) Comorbidities in australian women with hormone-dependent breast cancer: a population-based analysis. Med J Aust 208(1):24–28
doi: 10.5694/mja17.00006
pubmed: 29320669
Rao S, Prasad K, Abraham S, George T, Chandran SK, Baliga MS (2020) Incidence of hyperglycemia/secondary diabetes in women who have undergone curative chemotherapy for breast cancer: first study from India. South Asian J Cancer 9(3):130–135
doi: 10.1055/s-0041-1723104
pubmed: 33937134
Santorelli ML, Hirshfield KM, Steinberg MB, Rhoads GG, Lin Y, Demissie K (2016) Hormonal therapy for breast cancer and diabetes incidence among postmenopausal women. Ann Epidemiol 26(6):436–440
doi: 10.1016/j.annepidem.2016.04.004
pubmed: 27157863
Tamez-Pérez HE, Quintanilla-Flores DL, Rodríguez-Gutiérrez R, González-González JG, Tamez-Peña AL (2015) Steroid hyperglycemia: prevalence, early detection and therapeutic recommendations: a narrative review. World J Diabetes 6(8):1073–1081
doi: 10.4239/wjd.v6.i8.1073
pubmed: 26240704
pmcid: 4515447
Hwang JL, Weiss RE (2014) Steroid-induced diabetes: a clinical and molecular approach to understanding and treatment. Diabetes Metab Res Rev 30(2):96–102
doi: 10.1002/dmrr.2486
pubmed: 24123849
pmcid: 4112077
Vance V, Mourtzakis M, McCargar L, Hanning R (2011) Weight gain in breast cancer survivors: prevalence, pattern and health consequences. Obes Rev 12(4):282–294
doi: 10.1111/j.1467-789X.2010.00805.x
pubmed: 20880127
Winer EP, Hudis C, Burstein HJ, Wolff AC, Pritchard KI, Ingle JN, Chlebowski RT, Gelber R, Edge SB, Gralow J et al (2005) American society of clinical oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor–positive breast cancer: status report 2004. J Clin Oncol 23(3):619–629
doi: 10.1200/JCO.2005.09.121
pubmed: 15545664
Nyrop KA, Williams GR, Muss HB, Shachar SS (2016) Weight gain during adjuvant endocrine treatment for early-stage breast cancer: what is the evidence? Breast Cancer Res Treat 158(2):203–217
doi: 10.1007/s10549-016-3874-0
pubmed: 27342454
Dang C, Guo H, Najita J, Yardley D, Marcom K, Albain K, Rugo H, Miller K, Ellis M, Shapira I et al (2016) Cardiac outcomes of patients receiving adjuvant weekly paclitaxel and trastuzumab for node-negative, ERBB2-positive breast cancer. JAMA Oncol 2(1):29–36
doi: 10.1001/jamaoncol.2015.3709
pubmed: 26539793
pmcid: 5654518